Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Surzebiclimab
DRUG
2 trials
Sponsors
BeiGene
, BeOne Medicines
Conditions
Advanced Malignancies
HNSCC for Phase 2 Dose Expansion
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
NSCLC for Phase 2 Dose Expansion
Phase 1
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
Completed
NCT03744468
BeiGene
HNSCC for Phase 2 Dose Expansion, Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, NSCLC for Phase 2 Dose Expansion
Start: 2018-11-13
End: 2025-02-06
Updated: 2026-04-02
Phase 3
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Active, not recruiting
NCT04164199
BeOne Medicines
Advanced Malignancies
Start: 2019-12-19
End: 2026-07-01
Updated: 2026-03-27
Related Papers
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
2023-07-20
10 citations
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
Clinical Cancer Research
2021-10-29
44 citations
Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
Journal of Clinical Oncology
2020-05-20
12 citations